Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer
Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Susan Dent, Tamara Shenkier, Sukhbinder Dhesy-Thind, Susan L. Ellard, Catherine Prady, Muhammad Salim, Patricia Farmer, Ghasson Allo, Ming Sound Tsao, Alison Allan, Olga Ludkovski, Maria Bonomi, Dongsheng Tu, Linda Hagerman, Rachel Goodwin, Elizabeth Eisenhauer, Penelope Bradbury
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer'. Together they form a unique fingerprint.